Neuroprotection is unlikely to be effective in humans using current trial designs

Stroke

Volumn 33, Issue 1, 2002, Pages 306-307

  Grotta, James ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Animal models; Clinical trials; Neuroprotection; Stroke assessment

Indexed keywords

NEUROPROTECTIVE AGENT;

BRAIN PERFUSION; BRAIN PROTECTION; DISEASE SEVERITY; HUMAN; NEUROPROTECTION; PRIORITY JOURNAL; SCORING SYSTEM; SHORT SURVEY; STROKE; TREATMENT OUTCOME;

EID: 0036141160     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/str.33.1.306     Document Type: Short Survey

References (7)

1. Tissue plasminogen activator for acute ischemic stroke
2. Intravenous ancrod for treatment of acute ischemic stroke the STAT study: A randomized controlled trial
3. Intra-arterial prourokinase for acute ischemic stroke the PROACT II study: A randomized controlled trial
4. Generalized efficacy of t-PA for acute stroke: Subgroup analysis of the NINDS t-PA stroke trial
5. Temporal thresholds for neocortical infarction in rats subjected to reversible focal cerebral ischemia
6. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS)
7. Combination therapy stroke trial: Recombinant tissue-type plasminogen activator with/without lubeluzole